UAB To Test Potential COVID-19 Vaccine
By BirminghamWatch
The University of Alabama at Birmingham and the biopharmaceutical company Altimmune Inc. will test a potential vaccine for COVID-19, the university announced today.
Testing of the vaccine, AdCOVID, which was developed by the company based in Gaithersburg, Maryland, will begin in mice during the second quarter of this year. That phase of testing, designed to show the immune response to the drug in mice, is expected to take one to two months, UAB said in announcing the collaboration.
The vaccine is given in a single dose of intranasal spray, UAB said. If results of the tests in mice warrant, Altimmune could launch a Phase 1 human safety trial during the third quarter of this year.
The announcement by UAB said Altimmune “has significant experience in the development of intranasal vaccine candidates for respiratory pathogens, including a seasonal and pandemic influenza vaccine and a vaccine for inhalation anthrax.”
“We are eager to collaborate with Altimmune on this important project,” said Frances E. Lund, the Charles H. McCauley Professor and Chair for the UAB Department of Microbiology. “The expertise and infrastructure at UAB will be invaluable to the rapid progression of this vaccine into clinical studies.
Lund said six labs at UAB will work on the project.
Vipin K. Garg, president and CEO of Altimmune, cited UAB’s role in research in virology and immunology. He said the company was founded through a technology license from UAB in 1997.
“It is critical that the biotechnology industry and academic institutions work together to prevent the further spread of COVID-19, and UAB is an ideal partner to support us in this effort,”Garg said.
UAB also has extensive experience in conducting clinical studies of vaccines and has participated in studies sponsored by the Vaccine Evaluation and Trial Unit, part of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health.
The vaccine being tested “will activate mucosal and cellular immune responses, as well as a strong antibody response in the blood,” the announcement said.
“If the AdCOVID vaccine candidate is as stable as Altimmune’s influenza and anthrax vaccines candidates, that may allow inexpensive and efficient distribution of the millions of doses needed for widespread vaccination of populations,” the statement said.
NIH scientists call on director to protect biomedical research
In a public letter, hundreds of scientists expressed their dissent to the Trump administration's policies affecting the National Institutes of Health and called on its director to support the agency.
Netflix’s ‘The Eternaut’ makes a haunting series of an esteemed Argentine comic
El Eternauta has acquired near-mythic status in Argentina since it was first published in 1957.
This city is exploring an unconventional solution to water scarcity: sewage
A booming population and changing climate have strained water supplies in St. George, Utah. Local leaders are betting that recycled wastewater can keep the city's taps flowing.
President Trump said he fired a Smithsonian museum director. Can he do that?
Since taking office, President Trump has aggressively tried to reshape cultural institutions. Last month, he claimed he was firing the director of the Smithsonian's National Portrait Gallery.
4 things to know about the immigration raid protests that roiled LA this weekend
Protesters opposed to federal immigration raids faced off with law enforcement in Los Angeles over the weekend. President Trump called in the National Guard against the wishes of the governor.
Trump’s trade war is raising money for the government, but at whose expense?
Tariff collections are up sharply in the last 2 months. Congressional forecasters say tariffs could help reduce the federal debt, but they'll also lead to higher inflation and slower economic growth.
